Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

OBJECTIVE—We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndrome and according to various features of metabolic syndrome defined by the Adult Treatment Panel III (ATP III) in subjects with type 2 diabetes in the F...

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, Russell, O'Brien, Richard, Fulcher, Greg, Pardy, Chris, d'Emden, Michael, Tse, Dana, Taskinen, Marja-Riitta, Ehnholm, Christian, Keech, Anthony
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2009
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646035/
https://www.ncbi.nlm.nih.gov/pubmed/18984774
http://dx.doi.org/10.2337/dc08-1543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646035/
https://www.ncbi.nlm.nih.gov/pubmed/18984774
http://dx.doi.org/10.2337/dc08-1543

Ejemplares similares